This suggests that for ALK rearranged intracranial IMT, a combined approach of ALK inhibition and radiotherapy could be a highly effective treatment regimen, capitalizing on the synergistic effect of these therapies to overcome the limited drug penetration across the blood–brain barrier [88]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.